Windlas Biotech Intrinsic Value
WINDLAS • Healthcare
Current Stock Price
₹736.75
Primary Intrinsic Value
₹746.24
Market Cap
₹810.4 Cr
+6.6%
Upside
Median Value
₹785.45
Value Range
₹221 - ₹1474
Assessment
Trading Near Calculated Value
Safety Margin
6.2%
WINDLAS Valuation Methods Summary
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹746.24 | ₹596.99 - ₹895.49 | +1.3% | EPS: ₹33.92, Sector P/E: 22x |
| Book Value Method | asset | ₹920.00 | ₹828.00 - ₹1012.00 | +24.9% | Book Value/Share: ₹460.00, P/B: 2.0x |
| Revenue Multiple Method | revenue | ₹1473.50 | ₹1326.15 - ₹1620.85 | +100.0% | Revenue/Share: ₹821.82, P/S: 2.0x |
| EBITDA Multiple Method | earnings | ₹1163.64 | ₹1047.28 - ₹1280.00 | +57.9% | EBITDA: ₹128.00Cr, EV/EBITDA: 10x |
| Simple DCF (5Y) | dcf | ₹839.70 | ₹671.76 - ₹1007.64 | +14.0% | CF Growth: 15.0%, Discount: 15% |
| PEG Ratio Method | growth | ₹221.03 | ₹198.93 - ₹243.13 | -70.0% | EPS Growth: 8.0%, Fair P/E: 6.4x |
| Growth Adjusted P/E | growth | ₹524.06 | ₹471.65 - ₹576.47 | -28.9% | Revenue Growth: 6.0%, Adj P/E: 15.5x |
| ROE Based Valuation | profitability | ₹785.45 | ₹706.91 - ₹864.00 | +6.6% | ROE: 14.2%, P/E Multiple: 12x |
| Graham Defensive Method | conservative | ₹592.51 | ₹533.26 - ₹651.76 | -19.6% | EPS: ₹33.92, BVPS: ₹460.00 |
Method Types:
Earnings
Asset
DCF
Growth
Dividend
Conservative
Valuation Comparison Chart
WINDLAS Intrinsic Value Analysis
What is the intrinsic value of WINDLAS?
Based on our comprehensive analysis using 9 different valuation methods, the estimated intrinsic value of Windlas Biotech (WINDLAS) is ₹785.45 (median value). With the current market price of ₹736.75, this represents a +6.6% variance from our estimated fair value.
The valuation range spans from ₹221.03 to ₹1473.50, indicating ₹221.03 - ₹1473.50.
Is WINDLAS undervalued or overvalued?
Based on our multi-method analysis, Windlas Biotech (WINDLAS) appears to be trading near calculated value by approximately 6.6%.
Financial Health Analysis
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 105.00 | Industry Standard: 2.0+ | Above 2.0 | Measures short-term liquidity capacity |
| Return on Equity | 14.2% | Industry Standard: 15%+ | Above 10% | Measures shareholder return efficiency |
| Operating Margin | 13.0% | Industry Standard: 20%+ | Above 10% | Indicates operational efficiency level |
| Asset Turnover Ratio | 1.19x | Industry Standard: 1.0x+ | Above 1.0x | Measures asset utilization efficiency |
Related Pages for Windlas Biotech
Additional stock information and data for WINDLAS
Cash Flow Quality Analysis
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2025 | ₹68 Cr | ₹31 Cr | Positive Free Cash Flow | 7/10 |
| March 2024 | ₹109 Cr | ₹63 Cr | Positive Free Cash Flow | 8/10 |
| March 2023 | ₹61 Cr | ₹54 Cr | Positive Free Cash Flow | 8/10 |
| March 2022 | ₹9 Cr | ₹-69 Cr | Positive Operating Cash Flow | 6/10 |
| March 2021 | ₹12 Cr | ₹2 Cr | Positive Free Cash Flow | 7/10 |